Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia by Kwak, Jae-Yong, Kim, Sung-Hyun, Oh, Suk Joong, Zang, Dae Young, Kim, Hawk, Kim, Jeong-A, Do, Young Rok, Kim, Hyeoung Joon, Park, Joon Seong, Choi, Chul Won, Lee, Won Sik, Mun, Yeung-Chul, Kong, Jee Hyun, Chung, Joo Seop, Shin, Ho-Jin, Kim, Dae-Young, Park, Jinny, Jung, Chul Won, Bunworasate, Udomsak, Comia, Narcisa Sonia, Jootar, Saengsuree, Reksodiputro, Arry Harryanto, Caguioa, Priscilla B, Lee, Sung-Eun, Kim, Dong-Wook

Get full text

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial by Kantarjian, Hagop, Pasquini, Ricardo, Hamerschlak, Nelson, Rousselot, Philippe, Holowiecki, Jerzy, Jootar, Saengsuree, Robak, Tadeusz, Khoroshko, Nina, Masszi, Tamas, Skotnicki, Aleksander, Hellmann, Andrzej, Zaritsky, Andrey, Golenkov, Anatoly, Radich, Jerald, Hughes, Timothy, Countouriotis, Athena, Shah, Neil

Get full text

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors by Kim, Sung-Hyun, Menon, Hari, Jootar, Saengsuree, Saikia, Tapan, Kwak, Jae-Yong, Sohn, Sang-Kyun, Park, Joon Seong, Jeong, Seong Hyun, Kim, Hyeoung Joon, Kim, Yeo-Kyeoung, Oh, Suk Joong, Kim, Hawk, Zang, Dae Young, Chung, Joo Seop, Shin, Ho Jin, Do, Young Rok, Kim, Jeong-A, Kim, Dae-Young, Choi, Chul Won, Park, Sahee, Park, Hye Lin, Lee, Gong Yeal, Cho, Dae Jin, Shin, Jae Soo, Kim, Dong-Wook

Get full text

Chronic myeloid leukemia in Asia by Au, Wing Y., Caguioa, Priscilla B., Chuah, Charles, Hsu, Szu Chun, Jootar, Saengsuree, Kim, Dong-Wook, Kweon, Il-Young, O’Neil, William M., Saikia, Tapan K., Wang, Jianxiang

Get full text

Cost-Utility Analysis of Dasatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Refractory to First-Line Treatment With Imatinib in Thailand by Kulpeng, Wantanee, MSc, Sompitak, Sumalai, BSc, Jootar, Saengsuree, MD, Chansung, Kanchana, MD, Teerawattananon, Yot, MD, PhD

Get full text

The use of hematocrit level for predicting the efficiency of peripheral blood CD34+ cell collection after G-CSF Mobilization in Healthy Donors by Pornprasertsud, Nida, Niparuck, Pimjai, Kidkarn, Ruangtong, Puavilai, Teeraya, Sirachainan, Nongnuch, Pakakasama, Samart, Hongeng, Suradej, Jootar, Saengsuree, Ungkanont, Artit

Get full text

Chronic myeloid leukemia in the Asia-Pacific region: Current practice, challenges and opportunities in the targeted therapy era by Kim, Dong-Wook, Banavali, Shripad D, Bunworasate, Udomsak, Goh, Yeow-Tee, Ganly, Peter, Huang, He, Irving, Ian, Jootar, Saengsuree, Goh, Hyun-Gyung, Koh, Liang-Piu, Li, Wei, Naoe, Tomoki, Ng, Soo-Chin, Purushotaman, Visalachy, Reksodiputro, Harryanto, Shih, Lee-Yung, Tang, Jih-Luh, Tojo, Arinobu, Wang, Jianmin, Wong, Raymond

Get full text

Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia by Kim, Dong-Wook, Goh, Yeow-Tee, Hsiao, Hui-Hua, Caguioa, Priscilla B., Kim, Dongho, Kim, Wan-Seok, Saikia, Tapan, Agrawal, Shruti, Roy, Amit, Dai, David, Bradley-Garelik, M. Brigid, Mukhopadhyay, Jaydip, Jootar, Saengsuree

Get full text

Expanding Nilotinib Access in Clinical Trials (ENACT) by Nicolini, Franck E., Turkina, Anna, Shen, Zhi‐Xiang, Gallagher, Neil, Jootar, Saengsuree, Powell, Bayard L., De Souza, Carmino, Zheng, Ming, Szczudlo, Tomasz, le Coutre, Philipp

Get full text

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts by Abboud, Camille, Berman, Ellin, Cohen, Adam, Cortes, Jorge, DeAngelo, Daniel, Deininger, Michael, Devine, Steven, Druker, Brian, Fathi, Amir, Jabbour, Elias, Jagasia, Madan, Kantarjian, Hagop, Khoury, Jean, Laneuville, Pierre, Larson, Richard, Lipton, Jeffrey, Moore, Joseph O., Mughal, Tariq, O’Brien, Susan, Pinilla-Ibarz, Javier, Quintas-Cardama, Alfonso, Radich, Jerald, Reddy, Vishnu, Schiffer, Charles, Shah, Neil, Shami, Paul, Silver, Richard T., Snyder, David, Stone, Richard, Talpaz, Moshe, Tefferi, Ayalew, Van Etten, Richard A., Wetzler, Meir, Abruzzese, Elisabetta, Apperley, Jane, Breccia, Massimo, Byrne, Jenny, Cervantes, Francisco, Chelysheva, Ekaterina, Clark, R. E., de Lavallade, Hugues, Dyagil, Iryna, Gambacorti-Passerini, Carlo, Goldman, John, Haznedaroglu, Ibrahim, Hjorth-Hansen, Henrik, Holyoake, Tessa, Huntly, Brian, le Coutre, Philipp, Lomaia, Elza, Mahon, Francois-Xavier, Marin-Costa, David, Martinelli, Giovanni, Mayer, Jiri, Milojkovic, Dragana, Olavarria, Eduardo, Porkka, Kimmo, Richter, Johan, Rousselot, Philippe, Saglio, Giuseppe, Saydam, Guray, Stentoft, Jesper, Turkina, Anna, Vigneri, Paolo, Zaritskey, Andrey, Aguayo, Alvaro, Ayala, Manuel, Bendit, Israel, Maria Bengio, Raquel, Best, Carlos, Bullorsky, Eduardo, Cervera, Eduardo, DeSouza, Carmino, Fanilla, Ernesto, Gomez-Almaguer, David, Hamerschlak, Nelson, Lopez, Jose, Magarinos, Alicia, Meillon, Luis, Milone, Jorge, Moiraghi, Beatriz, Pasquini, Ricardo, Pavlovsky, Carolina, Ruiz-Arguelles, Guillermo J., Spector, Nelson, Arthur, Christopher, Browett, Peter, Grigg, Andrew, Hu, Jianda, Huang, Xiao-jun, Hughes, Tim, Jiang, Qian, Jootar, Saengsuree, Kim, Dong-Wook, Malhotra, Hemant, Malhotra, Pankaj, Matsumura, Itaru, Melo, Junia, Ohnishi, Kazunori

Get full text

Dasatinib or High-Dose Imatinib for Chronic-Phase Chronic Myeloid Leukemia Resistant to Imatinib at a Dose of 400 to 600 Milligrams Daily: Two-Year Follow-Up of a Randomized Phase... by KANTARJIAN, Hagop, PASQUINI, Ricardo, SHAH, Neil P, LEVY, Vincent, JOOTAR, Saengsuree, HOLOWIECKI, Jerzy, HAMERSCHLAK, Nelson, HUGHES, Timothy, BLEICKARDT, Eric, DEJARDIN, David, CORTES, Jorge

Get full text

Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily by Kantarjian, Hagop, Pasquini, Ricardo, Lévy, Vincent, Jootar, Saengsuree, Holowiecki, Jerzy, Hamerschlak, Nelson, Hughes, Timothy, Bleickardt, Eric, Dejardin, David, Cortes, Jorge, Shah, Neil P.

Get full text

Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A... by Limsuwanachot, Nittaya, Kongruang, Adcharee, Rerkamnuaychoke, Budsaba, Singdong, Roongrudee, Niparuck, Pimjai, Jootar, Saengsuree, Siriboonpiputtana, Teerapong

Get full text

Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand by Niparuck, Pimjai, Sorakhunpipitkul, Ladda, Atichartakarn, Vichai, Chuncharunee, Suporn, Ungkanont, Artit, Aungchaisuksiri, Pantep, Puavilai, Teeraya, Jootar, Saengsuree

Get full text

Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE) by Do, Young Rok, Kwak, Jae‐Yong, Kim, Jeong A., Kim, Hyeoung Joon, Chung, Joo Seop, Shin, Ho‐Jin, Kim, Sung‐Hyun, Bunworasate, Udomsak, Choi, Chul Won, Zang, Dae Young, Oh, Suk Joong, Jootar, Saengsuree, Reksodiputro, Ary Harryanto, Lee, Won Sik, Mun, Yeung‐Chul, Kong, Jee Hyun, Caguioa, Priscilla B., Kim, Hawk, Park, Jinny, Kim, Dong‐Wook

Get full text

Impact of Early Switching to Nilotinib As Second Line TKI in Patients with Chronic Myeloid Leukemia Who Were Intolerant to, Suboptimal to and Failed Imatinib: The Thai Multi-Center... by Viboonjuntra, Pongtep, Lekhakula, Arnuparp, Chansung, Kanchana, Sirijerachai, Chittima, Niparuck, Pimjai, Pauvilai, Teeraya, Numbenjapon, Tontanai, Bunworasate, Udomsak, Nawarawong, Weerasak, Tantiworawit, Adisak, Suwanban, Tawatchai, Jootar, Saengsuree

Get full text

Expanding Nilotinib Access in Clinical Trials (ENACT): An Open-Label, Multicenter Study of Oral Nilotinib in Adult Patients With Imatinib-Resistant or Imatinib-Intolerant Philadelp... by NICOLINI, Franck E, TURKINA, Anna, SHEN, Zhi-Xiang, GALLAGHER, Neil, JOOTAR, Saengsuree, POWELL, Bayard L, DE SOUZA, Carmino, MING ZHENG, SZCZUDLO, Tomasz, LE COUTRE, Philipp

Get full text

Nilotinib As Second-Line Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase: Thailand Experience by Chansung, Kanchana, Sirijerachai, Chittima, Lekhakula, Arnuparp, Viboonjuntra, Pongtep, Niparuck, Pimjai, Pauvilai, Teeraya, Numbenjapon, Tontanai, Bunworasate, Udomsak, Nawarawong, Weerasak, Tantiworawit, Adisak, Suwanban, Tawatchai, Jootar, Saengsuree

Get full text

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up by Do, Young Rok, Kwak, Jae-Yong, Kim, Hawk, Kim, Jeong-A, Kim, Hyeoung-Joon, Park, Joon Seong, Chung, Jooseop, Shin, Ho-Jin, Kim, Sung-Hyun, Bunworasate, Udomsak, Choi, Chul Won, Comia, Narcisa Sonia Cornejo, Zang, Dae Young, Oh, Sukjoong, Jootar, Saengsuree, Reksodiputro, Ary Harryanto, Lee, Won-Sik, Mun, Yeung-Chul, Kong, Jee Hyun, Caguioa, Priscilla B., Park, Jinny, Jung, Chul W., Kim, Dong-Wook

Get full text

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial by Coiffier, Bertrand, Prof, Osmanov, Evgenii A, Prof, Hong, Xiaonan, Prof, Scheliga, Adriana, MD, Mayer, Jiri, Prof, Offner, Fritz, Prof, Rule, Simon, MD, Teixeira, Adriana, MD, Walewski, Jan, Prof, de Vos, Sven, MD, Crump, Michael, Prof, Shpilberg, Ofer, Prof, Esseltine, Dixie-Lee, MD, Zhu, Eugene, PhD, Enny, Christopher, BS, Theocharous, Panteli, PhD, van de Velde, Helgi, MD, Elsayed, Yusri A, MD, Zinzani, Pier Luigi, Prof

Get full text